Spotlight on GR39821- Phase 1 Single & Multiple-Dose Safety Study of Anti-High Temperature Requirement A1 (HtrA1) in GA

Time: 2:00 pm
day: Track 1 Day 2 PM


  • Therapeutic Hypothesis for Targeting HtrA1
  • Review of GR39821 Phase 1 open-label, multicenter, single-and multiple-dose study of anti-HtrA1 in patients with GA secondary to AMD
  • Review ocular specific enzyme activity-based antiHtra1 PD assay